Learn what deucravacitinib is, how selective TYK2 inhibition works, and key clinical trial results in moderate-to-severe plaque psoriasis. Discover its mechanism, benefits over traditional JAK inhibitors, and potential role as an oral alternative to biologics.
Learn what deucravacitinib is, how its selective TYK2 inhibition differs from traditional JAK inhibitors, and why it’s reshaping treatment for plaque psoriasis and other autoimmune diseases with a potentially improved safety profile.